XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

What happened: The Japan Patent Office issued a Decision to Grant a patent for XORTX Therapeutics' Japanese Patent Application No. Why it matters: XORTX states this is expected to be the XRx-101 program's first patent protection in Japan, one of the world's largest pharmaceutical markets, and says it strengthens the intellectual property position of its xanthine oxidase inhibitor platform. The company has not entered into any partnering or licensing agreement regarding XRx-101.

The Japan Patent Office issued a Decision to Grant a patent for XORTX Therapeutics' Japanese Patent Application No.

XORTX states this is expected to be the XRx-101 program's first patent protection in Japan, one of the world's largest pharmaceutical markets, and says it strengthens the intellectual property position of its xanthine oxidase inhibitor platform. The company has not entered into any partnering or licensing agreement regarding XRx-101.